Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]
Journal of Hepatocellular Carcinoma · 2026-11 · Volume 13 · 1-1
DOI: 10.2147/jhc.s672578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-11. Verfasst von Zeran Yang und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yang, Z., Li, J., & Jin, L. (2026). Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]. Journal of Hepatocellular Carcinoma, Volume 13, 1-1. https://doi.org/10.2147/jhc.s672578
Vancouver
Yang Z, Li J, Jin L. Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-1. doi:10.2147/jhc.s672578
BibTeX
@article{Yang2026,
author = {Yang, Zeran and Li, Jian and Jin, Long},
title = {Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--1},
doi = {10.2147/jhc.s672578}
}
EUVIMED